Form 4: ZVRA SVP Sells 3,000 Shares Under 10b5-1 Plan

ZEVRA Therapeutics SVP of Finance and Corporate Controller, Timothy J. Sangiovanni, sold 3,000 shares of common stock for $9.1827 per share under a pre-arranged 10b5-1 plan.

Summary

• Timothy J. Sangiovanni, SVP, Finance & Corp Controller of ZEVRA THERAPEUTICS, INC. (ZVRA), reported a sale of common stock.
• The transaction involved the disposition of 3,000 shares of common stock.
• The shares were sold at a weighted average price of $9.1827 per share.
• This transaction was executed pursuant to a Rule 10b5-1(c) plan, which was adopted on March 28, 2025.
• Following this transaction, Timothy J. Sangiovanni beneficially owns 29,590 shares of ZEVRA THERAPEUTICS, INC. common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine insider transaction under a pre-arranged 10b5-1 plan, which typically does not signal a change in management's outlook on the company's prospects and therefore has a neutral sentiment.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider sales executed under Rule 10b5-1 plans are a common practice for corporate executives. These plans allow insiders to pre-arrange sales of company stock at a future date, providing an affirmative defense against claims of trading on material non-public information. Such transactions are typically viewed as routine personal financial management rather than a signal of management's changing sentiment about the company's prospects.

Stakeholder Impact

• Shareholders: The sale of 3,000 shares by an SVP is a relatively small transaction and is unlikely to have a significant impact on the company's stock price or investor sentiment, especially given it was pre-scheduled under a 10b5-1 plan.

Key Dates

Recommendation

The sale by a corporate officer was conducted under a pre-arranged 10b5-1 plan, which is a common practice for executives to manage personal liquidity and portfolio diversification. This type of transaction is generally not indicative of a change in the company's fundamental outlook or a signal for investors to alter their positions based solely on this filing. Therefore, a 'hold' recommendation is appropriate as this event does not provide new information to warrant a change in investment thesis.

Keywords

ZEVRA Therapeutics, ZVRA, Insider Sale, Form 4, Timothy J. Sangiovanni, 10b5-1 Plan, Common Stock